Diurnal Share Discussion Threads

[simon_64] 11/7/2022 13:24

best

I agree long term prospects here are excellent, like many other companies Covid screwed up their finances quite a bit, they haven't really done much wrong aprt from the director renumeration which was madness.

[best1467] 04/7/2022 07:14

If you listen to the share magazine presentation Richard stated they have signed severalNHS trusts and their original response may have painted a slightly more negative picture than they are facing.
So a glimmer of good news and each quarter gradually more countries are opening up so sale should continue to grow at an accelerated pace

[simon_64] 03/7/2022 12:20

Thanks weatherman. I knew they are going from one trust to another and have Wales signed up, i didn't know that England took their lead from Scotland.

[weatherman] 02/7/2022 16:26

For some reason many English NHS trusts take their lead from Scotland - so they are going from trust to trust to negotiate pricing. They are focussing more of their attention on countries such as Germany where Efmody has a pricing structure in place. We should get a trading update later this month.

[simon_64] 02/7/2022 13:16

Afternoon all.

I still can't quite fathom how the share price has dropped this low. I was thinking of adding when we were around 35pish,so glad i didn't.

I know we had a slowdown due to Covid and an issue with Scotland, but only a population of approx 7 million.

Any ideas,theories or comments welcome. ATB.

[best1467] 30/6/2022 19:26

Very polished presentation for a stand in CFO

[simon_64] 30/6/2022 15:11

Further every time i play golf up Heath Park just feel like putting in their windows pun intended.

[simon_64] 30/6/2022 13:52

Afternoon my long suffering fellow shareholders.

[best1467] 29/6/2022 07:54

Could be interesting are Eton lining up a bid for DNL THEY HAVE JUST SOLD RECEIVED $50 Million from sale to India’s DR REddy to solely focus on Rare disease portfolios.

[daveboy19] 28/6/2022 18:37

Yes. Martin just rang the Company from Miami Beach, requesting a top up of shares as his spending money is running low.

[aimmafia] 28/6/2022 17:33

Surprised there hasn't been another performance related rns giving away free shares to directors. I mean, they have done so well here

[c3479z] 27/6/2022 08:43

after dddd, it must be worrying for Dnl whether they can raise capital?

[mufprat] 22/6/2022 17:12

Sea off red again today. Can't believe I was so bullish about this company. Shareholders at 60p & 70p placings have been rinsed.

[tburns] 21/6/2022 18:54

Not far off now Aim!!

[aimmafia] 21/6/2022 17:28

I'm a buyer at 8p

[aimmafia] 13/6/2022 08:54

Still got more to go down.... Directors will be giving more free shares soon and performance based incentives. Absolute skull duggery

[best1467] 08/6/2022 09:18

Yes it’s slightly depressing thought but the same as happened to several in the sector. They got it completely wrong apparently with the expected market opportunity currently with Efmody so now with the PH3 to increase opportunity comes the risk and cash issue.
But a Mcap currently of 19Million it’s all priced in and more you could say

[tburns] 07/6/2022 18:07

I struggle to believe these were almost90p just over a year ago!

[weatherman] 07/6/2022 07:11

I don't know whether this will be available for Efmody(R) following SMC decision.

[daveboy19] 01/6/2022 14:29

Good luck with your other investments.

[simon_64] 01/6/2022 14:12

LOL1 DB.

I am considering picking up a few at this price.

I will see what RBD does in June before i make up my mind sitting on huge paper loss here at present like many others.

[daveboy19] 31/5/2022 16:42

Yes - I'm skint !!

[tburns] 31/5/2022 15:57

Anyone know what the cash position is here?

[weatherman] 13/5/2022 06:06

ETON PHARM. INC 12 May 22 1st Quarter "ALKINDI SPRINKLE® continues to grow and reported record quarterly revenue. More new patients initiated ALKINDI SPRINKLE® in the first quarter than any other quarter since the launch of the product. Eton’s co-promotion agreement with Tolmar Pharmaceuticals was fully implemented in January, which positively impacted product growth in the first quarter.

ALKINDI SPRINKLE® and carglumic acid continue to see strong growth and both posted record monthly revenue in April. The company expects 2022 revenue of at least $25 million, including $10 million of milestone payments and $15 million of product sales and royalties."